bioAffinity Technologies, Inc. (BIAF) - Net Assets
Based on the latest financial reports, bioAffinity Technologies, Inc. (BIAF) has net assets worth $7.28 Million USD as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($10.96 Million) and total liabilities ($3.68 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Read BIAF liabilities breakdown for a breakdown of total debt and financial obligations.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $7.28 Million |
| % of Total Assets | 66.4% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 108.92 |
bioAffinity Technologies, Inc. - Net Assets Trend (2019–2025)
This chart illustrates how bioAffinity Technologies, Inc.'s net assets have evolved over time, based on quarterly financial data. Also explore bioAffinity Technologies, Inc. (BIAF) total assets for the complete picture of this company's asset base.
Annual Net Assets for bioAffinity Technologies, Inc. (2019–2025)
The table below shows the annual net assets of bioAffinity Technologies, Inc. from 2019 to 2025. For live valuation and market cap data, see bioAffinity Technologies, Inc. market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $7.28 Million | +179.69% |
| 2024-12-31 | $2.60 Million | -46.41% |
| 2023-12-31 | $4.86 Million | -56.03% |
| 2022-12-31 | $11.04 Million | +169.94% |
| 2021-12-31 | $-15.79 Million | -4.76% |
| 2020-12-31 | $-15.07 Million | -273.50% |
| 2019-12-31 | $-4.04 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to bioAffinity Technologies, Inc.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 5363585900.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $31.46K | 0.43% |
| Other Components | $75.80 Million | 1041.55% |
| Total Equity | $7.28 Million | 100.00% |
bioAffinity Technologies, Inc. Competitors by Market Cap
The table below lists competitors of bioAffinity Technologies, Inc. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Academies Australasia Group Ltd
AU:AKG
|
$9.85 Million |
|
Universal Security Instruments Inc
NYSE MKT:UUU
|
$9.85 Million |
|
Edinburgh Worldwide Investment Trust plc
LSE:EWI
|
$9.86 Million |
|
Daekyo Co Ltd
KO:019685
|
$9.86 Million |
|
Fanhua Inc
F:4CIA
|
$9.84 Million |
|
Saxlund Group AB
ST:SAXG
|
$9.84 Million |
|
Orgenesis Inc
NASDAQ:ORGS
|
$9.83 Million |
|
Vigor Kobo Co Ltd
TWO:2733
|
$9.81 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in bioAffinity Technologies, Inc.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 2,602,036 to 7,277,656, a change of 4,675,620 (179.7%).
- Net loss of 14,909,754 reduced equity.
- New share issuances of 12,061,534 increased equity.
- Other factors increased equity by 7,523,840.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-14.91 Million | -204.87% |
| Share Issuances | $12.06 Million | +165.73% |
| Other Changes | $7.52 Million | +103.38% |
| Total Change | $- | 179.69% |
Book Value vs Market Value Analysis
This analysis compares bioAffinity Technologies, Inc.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.52x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | $-16.41 | $2.19 | x |
| 2020-12-31 | $-61.29 | $2.19 | x |
| 2021-12-31 | $-173.65 | $2.19 | x |
| 2022-12-31 | $73.64 | $2.19 | x |
| 2023-12-31 | $16.65 | $2.19 | x |
| 2024-12-31 | $6.44 | $2.19 | x |
| 2025-12-31 | $4.23 | $2.19 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently bioAffinity Technologies, Inc. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -204.87%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -241.96%
- • Asset Turnover: 0.56x
- • Equity Multiplier: 1.51x
- Recent ROE (-204.87%) is below the historical average (-112.80%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | 0.00% | 0.00% | 0.00x | 0.00x | $-2.90 Million |
| 2020 | 0.00% | 0.00% | 0.00x | 0.00x | $-5.76 Million |
| 2021 | 0.00% | -484411.41% | 0.00x | 0.00x | $-4.75 Million |
| 2022 | -73.84% | -169771.25% | 0.00x | 1.10x | $-9.26 Million |
| 2023 | -163.47% | -313.47% | 0.31x | 1.69x | $-8.42 Million |
| 2024 | -347.42% | -96.56% | 1.44x | 2.50x | $-9.30 Million |
| 2025 | -204.87% | -241.96% | 0.56x | 1.51x | $-15.64 Million |
Industry Comparison
This section compares bioAffinity Technologies, Inc.'s net assets metrics with peer companies in the Diagnostics & Research industry.
Industry Context
- Industry: Diagnostics & Research
- Average net assets among peers: $603,533,798
- Average return on equity (ROE) among peers: -223.45%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| bioAffinity Technologies, Inc. (BIAF) | $7.28 Million | 0.00% | 0.51x | $9.85 Million |
| Agilent Technologies Inc (A) | $2.51 Billion | -1.24% | 2.04x | $32.42 Billion |
| Advanced Biomed Inc. Common Stock (ADVB) | $3.49 Million | -115.35% | 0.92x | $7.19 Million |
| Applied DNA Sciences Inc (APDN) | $11.11 Million | -144.24% | 0.30x | $3.99 Million |
| Biodesix Inc (BDSX) | $4.58 Million | -1138.56% | 20.64x | $79.44 Million |
| Biocept Inc. (BIOCQ) | $11.20 Million | -224.43% | 0.58x | $262.00 |
| BillionToOne, Inc. Class A Common Stock (BLLN) | $30.47 Million | -271.32% | 5.29x | $3.21 Billion |
| Burning Rock Biotech Ltd (BNR) | $2.42 Billion | -16.82% | 0.10x | $154.44 Million |
| CareDx Inc (CDNA) | $430.91 Million | -17.78% | 0.26x | $1.00 Billion |
| Check Cap Ltd (CHEK) | $13.03 Million | -81.27% | 0.18x | $9.42 Million |
About bioAffinity Technologies, Inc.
bioAffinity Technologies, Inc. engages in developing non-invasive diagnostic laboratory tests to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis in the United States. The company operates through two segments: Diagnostic Research and Development; and Laboratory Services. The company offers CyPath lung which uses flow cytometry technology t… Read more